Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Neoplasms: early-phase trial registry
50 of 160 indexed Neoplasms trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #68 of 28,707 conditions by registered trial count.
160 US clinical trials · 50 currently recruiting · #68 of 28,707 conditions by registered trial count
Neoplasms: 160 US clinical trials tracked, 50 recruiting.
Neoplasms is the subject of 160 registered US clinical trials on ClinicalTrials.gov, 50 of them currently open to new participants. 9 are in Phase 3-4 (later-stage) and 99 in Phase 1-2 (earlier-stage). The most active sponsor is National Cancer Institute (NCI), running 15 of these trials.
Enrollment posture brief
Registry condition neoplasms
OPEN 50 | RECR 31% | LATE 9 | EARLY 99 | RANK #68 | SPON 15
Volume-matched condition peers
Nearest open-share peer: Aortic Valve Disease (31% recruiting · 16 trials)
Neoplasms lists 50 open slots (31% of 160 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Neoplasms on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Neoplasms is recruiting below its size-band peers.
50 of 160 indexed trials (31.3%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Neoplasms trials is spread across many organizations.
National Cancer Institute (NCI) accounts for 15 of 160 trials (9.4%). 85 distinct sponsors appear on at least one study for this condition label.
-
Typical Neoplasms enrolment sits around 81 participants.
Median target enrolment is 81 among the 159 trials that report a genuine target (sentinel values excluded). 87 of those (54.7%) plan for fewer than 100 participants.
-
Neoplasms research is mostly interventional.
130 interventional and 30 observational studies make up this index (81.3% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
160 total, page 1 of 4
AnovaOS Network Powered Patient Registry
Anova Enterprises
NCT05013944
RSSearch Patient Registry-Long Term Study of Use of SRS/SBRT
The Radiosurgery Society
NCT01885299
Registry Study for Radiation Therapy Outcomes
Proton Collaborative Group
NCT01255748
Cancer Experience Registry (CER) for Cancer Patients and Caregivers
Cancer Support Community, Research and Training Institute, Philadelphia
NCT02333604
Collection of Tissue Specimens From Patients With Solid Tumors or Blood Disorders and Their HLA-Compatible Family Members
National Heart, Lung, and Blood Institute (NHLBI)
NCT00071045
Clinical and Genetic Studies of Li-Fraumeni Syndrome
National Cancer Institute (NCI)
NCT01443468
Collection of Tissue Samples for Cancer Research
National Cancer Institute (NCI)
NCT00900198
Real World Registry for Use of the Ion Endoluminal System
Intuitive Surgical
NCT06004440
Sample Collection and Tracking for the Developmental Therapeutics Clinic
National Cancer Institute (NCI)
NCT03269578
Novel Serum Markers for Monitoring Response to Anti-Cancer Therapy
Stanford University
NCT00349830
Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells
Celgene
NCT03435796
Biennial CEM in Women With a Personal History of Breast Cancer
Wendie Berg
NCT06105749
Serious Gaming for Chemotherapy-induced Nausea and Vomiting
University of Central Florida
NCT05838638
A Study of GSK5764227 in Participants With. Advanced Solid Tumors (EMBOLD PanTumor-101)
GlaxoSmithKline
NCT06551142
AIMS Cancer Outcomes Study
Advanced Integrative Medical Science Institute
NCT04495790
Screening Strategies Among High-risk Populations for Anal Cancer
Lisa Flowers
NCT06628570
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Clinical Activity of GSK5733584 for Injection in Participants With Advanced Solid Tumors
GlaxoSmithKline
NCT06431594
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
Marengo Therapeutics
NCT05592626
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Clinical Activity of RO7673396 in Participants With Advanced Solid Tumors Harboring Rat Sarcoma Viral Oncogene Homolog (RAS) Mutation(s)
Hoffmann-La Roche
NCT06884618
A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABSK-021 in Patients With Advanced Solid Tumor
Abbisko Therapeutics Co
NCT04192344
Open-Label Study of Pocenbrodib Alone and in Combination With Abiraterone Acetate, Olaparib, or 177Lu-PSMA-617
Pathos AI
NCT06785636
Adoptive Cell Therapy Long-term Follow-up (LTFU) Study
Uswm CT
NCT03391778
A Study of JNJ-88549968 for the Treatment of Calreticulin (CALR)-Mutated Myeloproliferative Neoplasms
Janssen Research & Development
NCT06150157
A Study to Evaluate LY3537021 for the Treatment of Nausea and Vomiting Caused by Chemotherapy in Adults With Cancer
Eli Lilly and Company
NCT07169851
A Study of JNJ-87890387 for Advanced Solid Tumors
Janssen Research & Development
NCT06178614
EMB-01 in Patients With Advanced/Metastatic Gastrointestinal Cancers
Shanghai EpimAb Biotherapeutics Co.
NCT05176665
Barrett's Esophagus Related Neoplasia (BERN) Project
Midwest Biomedical Research Foundation
NCT00590239
A Study of AdAPT-001 in Subjects With Sarcoma and Refractory Solid Tumors
EpicentRx
NCT04673942
A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer
Eli Lilly and Company
NCT05999994
Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma
National Cancer Institute (NCI)
NCT06885697
Take the Reins: The Effects of Nutrient Timing on Cancer-related Fatigue
University of Maryland, Baltimore
NCT06482515
A Study of JNJ-87704916, as Monotherapy and in Combination for Advanced Solid Tumors
Johnson & Johnson Enterprise Innovation
NCT06311578
Resilience in East Asian Immigrants for Advance Care Planning Discussions
University of Illinois at Chicago
NCT06035549
A Study of GSK5764227 in Combination With Standard of Care (SoC) or Other Agents in Participants With Advanced Solid Tumors
GlaxoSmithKline
NCT07277270
Rapid Analysis and Response Evaluation of Combination Anti-Neoplastic Agents in Rare Tumors (RARE CANCER) Trial: RARE 1 Nilotinib and Paclitaxel
National Cancer Institute (NCI)
NCT04449549
A Study to Evaluate the Safety, PK/PD of (OriCAR-017) in Subjects With RR/MM - RIGEL Study
OriCell Therapeutics Co.
NCT06271252
Endometrial Cell Collection With the PadKit
Hackensack Meridian Health
NCT06464107
Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer
Stemline Therapeutics
NCT05386108
5-aza-4'-Thio-2'-Deoxycytidine (Aza-TdC) in People With Advanced Solid Tumors
National Cancer Institute (NCI)
NCT03366116
Bladder Fiducial Markers and Multiparametric-MRI (Mp-MRI) to Optimize Bladder Chemo-radiotherapy
Cedars-Sinai Medical Center
NCT04442724
Two Part Study of Nenocorilant Combined With Nivolumab in Patients With Advanced Solid Malignancies
Corcept Therapeutics
NCT07276373
Safety of SBRT With Anti-PD1 and Anti-IL-8 for the Treatment of Multiple Metastases in Advanced Solid Tumors and Melanoma
Yana Najjar
NCT04572451
A Study to Investigate the Safety and Preliminary Efficacy of GSK5460025 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors
GlaxoSmithKline
NCT07213609
A Study of [18F]LY4214835 in Healthy Volunteers and Participants With Cancer
Eli Lilly and Company
NCT07258836
Mobile Health Intervention to Improve Adherence to Oral Anticancer Therapy
University of California, Irvine
NCT07073807
Phase 1 Study of JV-394 Autologous Anti-CD94 CAR T for r/r CD94+ T/NK Cell Neoplasms
M.D. Anderson Cancer Center
NCT07382817
LITT Followed by Hypofractionated RT for Recurrent Gliomas
University of Maryland, Baltimore
NCT04181684
HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors
M.D. Anderson Cancer Center
NCT03911388
Feasibility of Remote Activity Assessment and PRO Collection Among Transgender Cancer Survivors
Cedars-Sinai Medical Center
NCT05391217
18F-Fluciclovine PET/CT Impact on Predicting Clinical Outcome of 177Lu-PSMA-617 Therapy in Patients With Prostate Cancer
VA Greater Los Angeles Healthcare System
NCT06706921
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 81 |
| Phase 2 | 18 |
| Phase 3 | 7 |
| Phase 4 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Neoplasms records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Neoplasms trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Neoplasms page
160 registered trials, 50 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 50 Neoplasms trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- National Cancer Institute (NCI) sponsors the most Neoplasms trials on record, review their full trial history before evaluating a specific study. See National Cancer Institute (NCI)'s trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Neoplasms condition card totals 160 registered trials; most-linked intervention Gemcitabine; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.